0.223
-0.12 (-34.41%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.06 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 0.26 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -78.94% | ||
| ROE | 245.74% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | -192.65% | ||
| GM | N/A | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | -0.43 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2 | ||
| Quick Ratio | 1.71 | ||
| Altman-Z | -7.74 |
ChartMill assigns a fundamental rating of 3 / 10 to OREX.
ChartMill assigns a valuation rating of 2 / 10 to OREXIGEN THERAPEUTICS INC (OREX). This can be considered as Overvalued.
OREXIGEN THERAPEUTICS INC (OREX) has a profitability rating of 3 / 10.
The Earnings per Share (EPS) of OREXIGEN THERAPEUTICS INC (OREX) is expected to decline by -499.11% in the next year.